2003
DOI: 10.1038/sj.bmt.1704291
|View full text |Cite
|
Sign up to set email alerts
|

Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

Abstract: Summary:The incidence of secondary myelodysplasia/acute myeloid leukemia (AML) was retrospectively assessed in an international joint study in 305 node-positive breast cancer patients, who received mitoxantrone-based high-dose chemotherapy (HDCT) followed by autologous stem cell support as adjuvant therapy. The median age of the patients was 57 years (range 22-67). In all, 268 patients received peripheral blood stem cells, and 47 patients received autologous bone marrow. After a median followup of 57 months (r… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
24
1

Year Published

2004
2004
2018
2018

Publication Types

Select...
6
1
1

Relationship

0
8

Authors

Journals

citations
Cited by 47 publications
(26 citation statements)
references
References 29 publications
1
24
1
Order By: Relevance
“…Alternatively, benzene metabolites may act more like dioxopiperazine and quinone topoisomerase II inhibitors than epipodophylotoxin inhibitors such as etoposide [Eastmond et al, 2005]. The former tend to induce leukemias with translocations t(8;21), inv(16), and t(15;17), and rarely t(11q23) [Xue et al, 1992;Zhang et al, 1993;Bhavnani and Wolstenholme, 1987;Kroger et al, 2003;Mistry et al, 2005]. Our previous finding of higher levels of t(8;21) in benzene-exposed workers ] is in agreement with this hypothesis, and the idea that benzene metabolites may induce leukemia in a manner similar to piperazine and quinone drugs warrants further exploration.…”
Section: Discussionmentioning
confidence: 95%
“…Alternatively, benzene metabolites may act more like dioxopiperazine and quinone topoisomerase II inhibitors than epipodophylotoxin inhibitors such as etoposide [Eastmond et al, 2005]. The former tend to induce leukemias with translocations t(8;21), inv(16), and t(15;17), and rarely t(11q23) [Xue et al, 1992;Zhang et al, 1993;Bhavnani and Wolstenholme, 1987;Kroger et al, 2003;Mistry et al, 2005]. Our previous finding of higher levels of t(8;21) in benzene-exposed workers ] is in agreement with this hypothesis, and the idea that benzene metabolites may induce leukemia in a manner similar to piperazine and quinone drugs warrants further exploration.…”
Section: Discussionmentioning
confidence: 95%
“…2 On the other hand, clinical and experimental data collected over the past decades suggest that MM could be successfully treated through (cellular) immunotherapy. 3,4 The curative potential of cellular immunotherapy in MM is illustrated by the induction of long-term sustained remissions after allogeneic stem cell transplantation or donor lymphocyte infusions in a subset of patients. 5,6 A highly appealing and more specific immunotherapy strategy for cancer is the adoptive transfer of cytotoxic T cells that are genetically engineered to express chimeric antigen receptors (CAR).…”
Section: Introductionmentioning
confidence: 99%
“…Despite differences in how these incidences were calculated (actuarial versus cumulative incidences), a risk of up to 10% for t-AML/MDS in patients who underwent ASCT for NHL was found when all studies through 1999 were considered together in a recent meta-analysis. 48 An increased risk of t-AML/MDS has also been seen in patients following ASCT performed for other indications such as breast cancer, 49,50 multiple myeloma 51 and germ cell tumors. 52 In general, the rate of t-AML/MDS seen after ASCT for these disorders is substantially lower than that observed in lymphoma patients who have undergone ASCT.…”
Section: Incidence Of T-aml/mds After Conventional Therapymentioning
confidence: 99%
“…55 This again suggests that pre-ASCT lymphoma therapy leads to genotoxic damage, which then causes the emergence of abnormal hematopoietic clones associated with t-AML/MDS. MDS and AML have been reported after transplantation for other malignancies, such as breast cancer, 49,50 multiple myeloma 51 and germ cell tumors. 52 The University of Arkansas group reported seven cases of MDS among 188 patients who underwent ASCT for myeloma.…”
Section: Evidence That Pre-transplant Therapy Determines Risk Of T-ammentioning
confidence: 99%